Comparison of nodal staging between CT, MRI, and \([^{18}\text{F}]\)-FDG PET/MRI in patients with newly diagnosed breast cancer

Janna Morawitz1, Nils-Martin Bruckmann1, Frederic Dietzel1, Tim Ullrich1, Ann-Kathrin Bittner2, Oliver Hoffmann2, Eugen Ruckhäberle3, Svjetlana Mohrmann3, Lena Häberle4, Marc Ingenwerth5, Daniel Benjamin Abrar1, Lino Morris Sawicki1, Katharina Breuckmann6, Wolfgang Peter Fendler7, Ken Herrmann7, Christian Buchbender1, Gerald Antoch1, Lale Umutlu6, Julian Kirchner1

Received: 26 April 2021 / Accepted: 20 July 2021 / Published online: 3 September 2021 © The Author(s) 2021, corrected publication 2022

Abstract

Purpose To compare CT, MRI, and \([^{18}\text{F}]\)-fluorodeoxyglucose positron emission tomography (\([^{18}\text{F}]\)-FDG PET/MRI) for nodal status, regarding quantity and location of metastatic locoregional lymph nodes in patients with newly diagnosed breast cancer.

Materials and methods One hundred eighty-two patients (mean age 52.7 ± 11.9 years) were included in this prospective double-center study. Patients underwent dedicated contrast-enhanced chest/abdomen/pelvis computed tomography (CT) and whole-body (\([^{18}\text{F}]\)-FDG PET/) magnet resonance imaging (MRI). Thoracic datasets were evaluated separately regarding quantity, lymph node station (axillary levels I–III, supraclavicular, internal mammary chain), and lesion character (benign vs. malign). Histopathology served as reference standard for patient-based analysis. Patient-based and lesion-based analyses were compared by a McNemar test. Sensitivity, specificity, positive and negative predictive values, and accuracy were assessed for all three imaging modalities.

Results On a patient-based analysis, PET/MRI correctly detected significantly more nodal positive patients than MRI (\(p < 0.0001\)) and CT (\(p < 0.0001\)). No statistically significant difference was seen between CT and MRI. PET/MRI detected 193 lesions in 75 patients (41.2%), while MRI detected 123 lesions in 56 patients (30.8%) and CT detected 104 lesions in 50 patients, respectively. Differences were statistically significant on a lesion-based analysis (PET/MRI vs. MRI, \(p < 0.0001\); PET/MRI vs. CT, \(p < 0.0001\); MRI vs. CT, \(p = 0.015\)). Subgroup analysis for different lymph node stations showed that PET/MRI detected significantly more lymph node metastases than MRI and CT in each location (axillary levels I–III, supraclavicular, internal mammary chain). MRI was superior to CT only in axillary level I (\(p = 0.0291\)).

Conclusion \([^{18}\text{F}]\)-FDG PET/MRI outperforms CT or MRI in detecting nodal involvement on a patient-based analysis and on a lesion-based analysis. Furthermore, PET/MRI was superior to CT or MRI in detecting lymph node metastases in all lymph node stations. Of all the tested imaging modalities, PET/MRI showed the highest sensitivity, whereas CT showed the lowest sensitivity, but was most specific.

Keywords Nodal staging · Breast cancer · PET/MR

Introduction

With more than 2 million cases in 2020, breast cancer is the most commonly diagnosed cancer worldwide [1]. Despite tumor biology, nodal involvement is one of the most significant prognostic factors at initial diagnosis of breast cancer [2, 3]. For breast cancer, locoregional lymph nodes are defined as ipsilateral axillary, supraclavicular, and internal mammary lymph nodes [4].

The likelihood of lymphatic drainage from the breast to axillary, internal mammary, infraclavicular, and supraclavicular lymph nodes are reported to be 98.2%, 35.3%, 1.7%, and 3.1% [5], but the location of lymph node metastases significantly depends on primary tumor location [6]. All further affected lymph nodes are considered distant metastasis. Nowadays, staging for primary breast cancer
patients consists of clinical examination, mammography, breast- and axillary ultrasound, bone scintigraphy, and thoraco-abdominal CT [7]. If clinical examination and/or imaging does not indicate nodal involvement, sentinel lymph node biopsy is the gold standard for axillary surgical approach in women with operable breast cancer. Axillary dissection has been the standard surgical treatment in breast cancer patients for several years, but axillary management has become less invasive, since studies revealed that sentinel lymph node biopsy and targeted axillary dissection have become equal to axillary dissection in clinically node negative and also in certain cases of nodal positive patients regarding local control and prognosis and come with a significantly reduced morbidity [8, 9]. Nevertheless, some studies showed that even in the case of a negative sentinel lymph node biopsy locoregional lymph node metastases are possible [10, 11]. Therefore, highly accurate imaging especially of locoregional lymph nodes becomes even more important in terms of treatment planning.

Involvement of movable axillary lymph nodes is classified as cN1, but it proceeds with involvement of fixed axillary lymph nodes to cN2a, with internal mammary lymph node involvement to cN2b, with infraclavicular involvement to cN3a, with simultaneous axillary and internal mammary lymph nodes to cN3b, and with supraclavicular lymph node involvement to cN3c [12]. This reflects the worsening of prognostic with progression of lymphatic metastasis. Several studies have shown patients with supraclavicular lymph node metastases to have a worse prognosis than patients with nodal involvement limited to axillary levels; nevertheless, TNM classification indicates that patients with supraclavicular lymph node metastases still have a better prognosis than patients with distant metastases [13], other than presumed first.

Although axillary ultrasound is of high value for the detection of axillary lymph node metastases, its value is limited for detection of internal mammary lymph nodes and also for fixed or grouped lymph node metastases. Reliable lymph node assessment especially in these regions is crucial not only for correct N-status and prognosis but also for therapy planning, e.g., in case of internal mammary nodal involvement, enlargement of irradiation field can be considered [14].

So far, studies have shown PET/CT to be superior to conventional imaging methods for nodal staging, but data comparing MRI or PET/MRI with established imaging for nodal staging is still limited. Therefore, the aim of the study was to compare the diagnostic performance of [18F]-FDG PET/MRI, MRI, and CT in exact nodal staging in patients with newly diagnosed breast cancer.

**Material and methods**

**Patients and inclusion criteria**

Patients with therapy-naive invasive breast cancer were included in the study if at least one of the following criteria for elevated risk for distant metastasis was present: (1) newly diagnosed, treatment-naive T2 tumor or higher T stage or (2) newly diagnosed, treatment-naive triple-negative tumor of every size or (3) newly diagnosed, treatment-naive tumor with molecular high risk to set elevated risk for metastases, according to the ESMO guidelines [15]. Patients were included in the study between March 2018 and September 2020. This prospective, double-center study was approved by the local ethics committees (study number 6040R and study number 17–7396-BO). Prior to enrolment, a written informed consent form was signed by all patients. Exclusion criteria were former malignancies in the past 5 years, contraindications for MRI or contrast agents, and pregnancy or breast feeding. Some of the patients were reported before but with different objectives [16, 17].

**PET/MRI protocol**

All patients underwent (PET/)MR imaging on an integrated 3-T hybrid PET/MRI system (Biograph mMR, Siemens Healthcare, Erlangen, Germany). Patients fasted for 6 h prior to the PET/MRI examination to ensure blood glucose levels were < 150 mg/dl. A weight-adapted dose of [18F]-FDG (4 MBq/kg body weight) was intravenously injected 1 h prior to examination. (PET/)MRI was conducted from head to mid-thigh in supine body position for staging purpose. Thoracal sections from whole-body imaging were analyzed for nodal staging.

PET images were reconstructed using the iterative ordered-subset expectation maximization (OSEM) algorithm, 3 iterations and 21 subsets, a Gaussian filter with 4-mm full width at half maximum (FWHM), and a 344 × 344 image matrix. For MR-based attenuation correction of the patient tissues, a two-point (fat, water) coronal 3D-Dixon-VIBE sequence was acquired to generate a four-compartment model (background air, lungs, fat, muscle).

The whole-body MRI protocol comprised the following sequences:

1. A transverse T2-w half Fourier acquisition single shot turbo spin echo (HASTE) sequence in breath-hold technique with a slice thickness of 7 mm (TE 97 ms; TR 1500 ms; turbo factor (TF) 194; FOV 400 mm; phase FOV 75%; acquisition matrix 320 × 240 mm; in plane resolution 1.3 × 1.3 mm; TA 0:47 min / bed position)
2. A transversal diffusion-weighted (DW) echo-planar imaging (EPI) sequence in free breathing with a slice thickness of 5.0 mm (TR 7400 ms; TE 72 ms; b-values: 0, 500, and 1000 s/mm², matrix size 160 × 90; FOV 400 mm × 315 mm, phase FOV, 75%; GRAPPA, acceleration factor 2; in-plane resolution 2.6 × 2.6 mm; TA 2:06 min / bed position)

3. A fat-saturated post-contrast transverse 3-dimensional volumetric interpolated breath-hold examination (VIBE) sequence with a slice thickness of 3 mm (TE, 1.53 ms; TR, 3.64 ms; flip angle 9°; FOV 400 × 280 mm; phase FOV 75%; acquisition matrix 512 × 384, in-plane resolution 0.7 × 0.7 mm; TA 0:19 min / bed position)

CT

CT examinations were performed on dedicated CT scanner (Siemens Flash, Siemens Somatom AS, Siemens Healthineers, Erlangen, Germany). Iodinated contrast medium was administered intravenously 70 s before the scan. CT was acquired using the manufacturer-supplied dose reduction CareKV and CareDose 4D.

Image analysis

Two experienced radiologists and a nuclear medicine specialist with large experience in hybrid imaging and especially PET/MR reading independently analyzed all (PET/) MRI datasets in random order utilizing an Osiris Workstation (Pixmeo SARL, Bernex, Switzerland). Readers were aware of the breast cancer diagnosis but were blinded to patients' history and identity and to results of distant metastasis. To avoid recognition bias, datasets were evaluated separately with a reading intermission of 4 weeks. Discordant readings were resolved in consensus reading. For every patient, each lymph node station (axillary I–III, supraclavicular, internal mammary chain) was evaluated separately for presence or absence and quantity of lymph node metastasis. Lymph node stations are defined according to the 8th edition of TNM classification as follows: Level I is found lateral from the lateral border of the M. pectoralis minor, level II extends from the lateral to the medial border and posterior to the muscle, while level III extends medial the medial border of the M. pectoralis minor and under the clavicle. Supraclavicular lymph nodes are found above the clavicle and medial from the M. sternocleidomastoideus [18], while internal mammary lymph nodes are located near the internal mammary vessels next to the sternum, mostly in the 1st–6th intercostal space [19, 20].

If applicable, morphologic features for the diagnosis of axillary and supraclavicular lymph node metastases were as follows: (a) short-axis diameter > 10 mm, (b) irregular margin, (c) inhomogeneous cortex, (d) perifocal edema, (e) absent fatty hilum, (f) asymmetry in comparison to contralateral site, (g) contrast media enhancement in comparison to surrounding and to contralateral lymph nodes, and (h) blurred nodal border. Lymph nodes in internal mammary chain were rated suspicious, when 2 or more lymph nodes were > 6 mm [21] or when increased tracer uptake was observed. In PET/MRI, in addition to the previously mentioned morphologic criteria, a tracer uptake above the direct background and the surrounding lymph nodes was considered a sign of malignancy. To measure SUVmax and SUVmean, a manually drawn region of interest was placed around the respective lymph node [22–24]. In accordance with previous publications reporting the superiority of PET uptake over morphology, also small and/or morphologic unsuspicious nodes were rated as malignant when showing elevated FDG uptake [25].

Reference standard

Histopathology of axillary lymph nodes served as reference standard for patient-based analysis in all patients. Sentinel lymph node biopsy or axilla dissection was used as reference standard, if available. Otherwise, pretherapeutic ultrasound-guided core needle biopsy was used as reference standard. If no sufficient pretherapeutic sampling of lymph nodes was available, sentinel lymph node excision or axilla dissection after neoadjuvant systemic therapy was used as reference standard. For this, additional histopathological preparations were evaluated, using focal fibrosis or focal necrosis as a retrospective indicator for previously vital lymph node metastasis [26, 27]. For lesion-based analysis, all histopathological samples as well as results of follow-up imaging (if available) and clinical follow-up were taken into account to determine the reference standard. Reduction in diameter following treatment was regarded as a sign of malignancy. Also, lesions with increasing size and those with enduring and increasing changes listed above (irregular margin, inhomogeneous cortex, perifocal edema, absent fatty hilum, asymmetry in comparison to contralateral site, contrast media enhancement, and blurred nodal border) were considered malignant.

Statistics

SPSS Statistics 26 (IBM Corp., Chicago, IL, USA) was used for statistical analysis. A p-value < 0.05 was considered statistically significant. Data are presented as mean ± standard deviation. A McNemar test was used to assess differences in lesion detection on a patient-based analysis and on a lesion-based analysis. Based on the reference standard for patient-based analysis, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Because of their location in internal mammary
chain, four PET positive, but morphologically not detectable, lymph node could not be saved histopathologically. In morphological follow-up imaging, these nodes were still not detectable; therefore, no reliable reference standard was available. To address this insoluble problem, the diagnostic performance was calculated for two different scenarios, on the one hand that PET/MRI rated these lymph nodes falsely positive and MRI as well as CT rated these lymph nodes correctly negative and vice versa.

Results

Patient population and reference standard

In this study, a total of 182 patients (mean age 52.7 ± 11.9 years) were prospectively included (Fig. 1). For patient demographics and primary tumor characteristics, see Table 1. For all patients, dedicated chest/thorax/pelvis CT, whole-body MRI, and whole-body [18F]-FDG PET/MRI (mean activity 278.53 ± 63.95 MBq) were available.

According to the reference standard, 109/182 patients (59.9%) were nodal negative and 73/182 patients (40.1%) were nodal positive. In 93/182 patients (51.1%), histological sampling of lymph nodes was conducted before systemic therapy (52 axillary core needle biopsies, 32 sentinel lymph node excisions, 9 axilla dissections), and in 89/182 patients (48.9%), sampling was conducted after systemic therapy (86 sentinel lymph node excision, 3 axillary dissections). A total of 194 lymph node metastases were detected in all three imaging modalities. In 104 patients, additional MRI follow-up imaging was used to confirm the reference standard.

Patient-based analysis and diagnostic performance

On a patient-based analysis, PET/MRI detected 60/73 (82.2%) nodal positive (N+) patients while classifying 13 patients as false negative (missing 17.8% of N+ patients). MRI correctly detected 51/73 (69.9%) N+ patients while classifying 22 patients as false negative (missing 30.1% of N+ patients) and CT detected 46/73 (63.0%) N+ patients while classifying 27 patients as false negative (missing 37.0% of N+ patients).

No additional patient was classified as N+ in CT or MRI compared to PET/MRI. Seven additional patients were correctly staged N+ in MRI but were missed in CT, while 3 other patients were correctly staged N+ in CT but were missed in MRI. In four patients, one single lymph node was suspicious for metastasis in PET/MRI due to elevated tracer uptake, but not in MRI or CT. Because of their location (a single internal mammary lymph node in three patients and an interpectoral lymph node in one patient), these lymph nodes could not be saved histopathologically, but reference standard (sentinel lymph node biopsy) was negative for all four patients. As described before, two different scenarios were calculated for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for each modality to solve this problem (see Table 2). On a patient-based analysis, differences between PET/MRI and MRI and between PET/MRI and CT were statistically significant (each \( p < 0.0001 \)). Differences between MRI and CT were statistically non-significant (\( p = 0.7893 \)).

Lesion-based analysis

CT detected 104 lymph node metastases, 69 of them in axillary level I, 34 in axillary level II, and one in internal mammary chain. MRI detected 123 lymph node metastases, 80 of them in axillary level I, 38 in axillary level II, two in axillary level III, and three in internal mammary chain. PET/MRI detected 193 lymph node metastases, 102 of them in axillary level I, 61 in axillary level II, 13 in axillary level III, one supraclavicular lymph node, and 16 internal mammary chain lymph nodes (Table 3). Overall differences in lesion-based detection rates were statistically significant (PET/MRI vs. MRI, \( p < 0.0001 \); PET/MRI vs. CT, \( p < 0.0001 \); MRI vs. CT, \( p < 0.0001 \)).
Subgroup analysis showed that differences between PET/MRI vs. MRI and PET/MRT vs. CT were statistically significant for each lymph node station. Differences between MRI and CT were statistically significant only for axillary level I, while differences for axillary level II + III, supraclavicular, and internal mammary stream were statistically non-significant (Table 4).

Compared to MRI, PET/MRI leads to an upstaging of nodal status in 30 patients, and compared to CT, PET/MRI led to an upstaging in 41 patients. No downstaging was observed in PET/MRI compared to that in MRI or CT. Compared to CT, MRI led to an upstaging of nodal status in 15 patients and to a downstaging in 6 patients.

**Discussion**

This study demonstrates the diagnostic superiority of [18F]-FDG PET/MRI over MRI and CT in determining the correct nodal status in axillary (levels I–III), supraclavicular, and internal mammary lymph nodes in patients with newly diagnosed breast cancer. On a patient-based analysis, PET/MRI correctly detected nodal involvement in significantly more patients and on a lesion-based analysis, PET/MRI detected significantly more lymph node metastases per lymph node station. As no adequate reference standard was available for a total of 4 lymph nodes along the internal mammary chain, two different scenarios were calculated: However, if the 95% CI intervals of both calculation bases are taken as a basis, it can be assumed that PET/MRI is superior to MRI with regard to overall accuracy. This is pooled for PET/MRI at 78.76 to 91.36% and for MRI at 76.6 to 85.25%.

Reliable and exact detection of nodal positive disease is crucial in breast cancer, not only for therapy planning, but also in terms of prognosis.

As several guidelines for breast cancer recommend sonography and CT for nodal staging of primary breast cancer patients [7], this is the imaging gold standard for assessment of nodal involvement so far. But studies have shown limited sensitivity of both imaging modalities: Alvarez et al. have postulated that sonography is of limited use to exclude nodal involvement due to its only moderate sensitivity [28]. Studies on the detection accuracy of lymph node metastases in CT are limited. Individual studies have shown that sensitivity of CT for the detection of axillary nodal involvement in breast cancer patients is 76.9%, although a short-axis diameter of 5 mm was set as the cutoff value for suspicious lymph nodes [29]. In our study, CT showed even lower sensitivity with only 63%. Due to its high sensitivity and high negative predictive value, some studies even suggest replacing sentinel lymph node biopsy by MRI [30, 31]. But compared to our study, dedicated axillary protocols were applied and/or lymph node-specific contrast agents were used. Contrary to these protocols, we examined the value of MRI in an every-day clinical setting and nearly similar to CT, MRI revealed a limited sensitivity with about 70%.

Studies with small patient cohorts even show the added value of PET/MRI in nodal staging of primary breast cancer.
Table 2 Diagnostic performance of PET/MRI, MRI, and CT on a patient-based analysis in differentiating N+ and N− status, when all 4 lymph nodes, that could not be saved histopathologically are (A) rated false positive in PET/MRI and true negative in MRI and CT or (B) rated true positive in PET/MRI and false negative in MRI and CT

|          | Sensitivity | Specificity | PPV      | NPV      | Accuracy   |
|----------|-------------|-------------|----------|----------|------------|
|          | (95% CI)    | (95% CI)    | (95% CI) | (95% CI) | (95% CI)   |
| A) PET/MRI | 82.43%      | 86.36%      | 80.26%   | 87.96%   | 84.78%     |
|          | (71.83 to 90.30%) | (78.51 to 92.16%) | (71.52 to 86.82%) | (81.61 to 92.33%) | (78.76 to 89.64%) |
| MRI      | 69.86%      | 95.45%      | 91.07%   | 82.68%   | 85.25%     |
|          | (58.00 to 80.06%) | (89.71 to 98.51%) | (81.04 to 96.05%) | (77.05 to 87.15%) | (79.26 to 90.05%) |
| CT       | 63.01%      | 96.36%      | 92.00%   | 79.70%   | 83.06%     |
|          | (50.91 to 74.03%) | (90.95 to 99.00%) | (81.22 to 96.83%) | (74.38 to 84.15%) | (76.83 to 88.19%) |
| B) PET/MRI | 83.12%      | 89.52%      | 85.33%   | 87.85%   | 86.81%     |
|          | (72.86 to 90.69%) | (82.03 to 94.65%) | (76.72 to 91.13%) | (81.43 to 92.26%) | (81.02 to 91.36%) |
| MRI      | 66.23%      | 95.24%      | 91.07%   | 79.36%   | 82.97%     |
|          | (54.55 to 76.62%) | (89.24 to 98.44%) | (81.03 to 96.06%) | (73.72 to 84.06%) | (76.70 to 88.12%) |
| CT       | 59.74%      | 96.19%      | 92.00%   | 76.52%   | 80.77%     |
|          | (47.94 to 70.77%) | (90.53 to 98.95%) | (81.21 to 96.83%) | (71.23 to 81.09%) | (74.28 to 86.22) |

PPV positive predictive value, NPV negative predictive value

Table 3 Number of suspicious lymph nodes in the different locations

|          | CT | MRI | PET/MRI |
|----------|----|-----|---------|
| Axillary level I | 69 | 80 | 102 |
| Axillary level II | 34 | 38 | 61 |
| Axillary level III | 0 | 2 | 13 |
| Supraclavicular | 0 | 0 | 1 |
| Internal mammary stream | 1 | 3 | 16 |
| Total | 104 | 123 | 193 |

patients, compared to conventional imaging methods as ultrasound and MRI [32, 33]. As PET/CT is an extensively studied imaging modality, various studies exist on the diagnostic performance of the detection of nodal involvement in primary breast cancer patients. In different prospective studies, a sensitivity from 56 to 77% is described [34–36]. For PET/CT, it is reported that false negative axillae had significantly smaller and fewer tumor positive lymph nodes than true positive axillae [37]. These findings go hand in hand with our study, demonstrating a sensitivity of PET/MRI in detecting nodal positive patients of over 80%.

Quantity of affected lymph nodes is of importance especially for planned radiotherapy. If >3 axillary lymph nodes are affected, the radiation field would include the infraclavicular and supraclavicular lymph nodes [38, 39]. Imaging is particularly important if lymph nodes other than the later removed sentinel lymph node are conspicuous in imaging. In addition, studies have shown that the sentinel lymph node can also be found outside the axilla, which entails the risk of underclassifying patients in whom a sentinel lymph node biopsy only includes axillary lymph nodes [40]. Other studies have shown that sentinel lymph nodes can also be located outside of predefined lymph node stations, the so-called interval nodes [5]. In this case, too, the removal of only axillary lymph nodes as sentinel lymph node biopsy carries the potential risk of false negativity. Therefore, in sentinel lymph node biopsy, preoperative imaging should always be considered with regard to conspicuous lymph nodes outside the axilla. Literature indicates that PET/CT can provide information about extra-axillary nodal involvement better than conventional imaging methods [41] and that the diagnosis of extra-axillary lymph node metastases with clinically well-established methods shows a lack of sensitivity. This is in line with our study, demonstrating the superiority of PET/MRI over MRI and CT in detecting lymph node metastases not only for axillary levels I–III, but also for supraclavicular and internal mammary nodes. For example, in our study, PET/MRI was the only imaging modality, which was able to detect supraclavicular nodal metastatic disease. Staging of internal mammary lymph nodes is controversial because there is no existing cutoff size for pathological enlargement and presence of internal mammary lymph nodes can also be observed in healthy individuals [42]. Therefore, especially increased metabolic activity in hybrid imaging is indicative for nodal metastasis [43]. This is underlined by the results of this study, as in some cases tracer uptake was seen in internal mammary chain without a certain morphological correlate. The therapeutic consequence of the additional internal mammary lymph node metastases detected in PET/MRI lies primarily in the extension of the radiation field with inclusion of the internal mammary chain [44], since most patients are treated neoadjuvantly anyway and resection of internal
mammary lymph nodes is very invasive and bears a high risk of complications.

Our study has some limitations. First of all, not all suspect lymph nodes are proven histopathologically. Mostly, sentinel lymph node or ultrasound-guided biopsies were taken from axillary level I or II. Also in the case of axillary dissection, sampling is limited to axillary levels I and II. In our study, supraclavicular lymph nodes and lymph nodes of the internal mammary chain were not proven histopathologically. Consequently, diagnostic performance could not be calculated for lesion-based analysis, but for patient-based analysis only. Furthermore, only one patient had a suspicious supraclavicular lymph node, but this is in line with literature reporting only 1–4% of patients without distant metastasis having supraclavicular lymph node metastasis [45]. Hence, statistical analysis for supraclavicular lymph nodes could not be made.

In conclusion, our prospective study demonstrates that PET/MRI localizes lymph node metastases with higher detection rate and accuracy than MRI and CT and that it can reliably be used for nodal staging in primary breast cancer patients. PET/MRI is superior not only in axillary levels I and II, which are commonly covered by sentinel lymph node biopsy and axillary dissection, but also in axillary level III, supraclavicular, and internal mammary lymph nodes, which may have impact on modified axillary dissection or...
enlargement of irradiation fields. Although diagnostic superiority could be shown, effects on patient outcome have to be evaluated in further prospective studies.

Funding Open Access funding enabled and organized by Projekt DEAL. The study is funded by the Deutsche Forschungsgemeinschaft (DFG), the German Research Foundation (BU3075/2–1; KI2434/1–2). The funding foundation was not involved in trial design, patient recruitment, data collection, analysis, interpretation or presentation, writing or editing of the reports, or the decision to submit for publication. The corresponding author had full access to all data in the study and had all responsibility for the decision to submit for publication.

Data Availability The authors ensure that all data and materials as well as software application support their published claims and comply with field standards.

Code availability Not applicable.

Declarations

Ethics approval All procedures were performed in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments.

Consent to participate Informed consent was obtained from all the individual participants included in the study.

Conflict of interest Wolfgang P. Fendler was a consultant for BTG, and he received fees from RadioMedix, Bayer, and Parexel outside of the submitted work. No other potential conflicts of interest relevant to this article exist.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. WHO. International Agency for Research on Cancer. World Health Organization - cancer today. In: Organization. IAIrCWH, editor.; 2021
2. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–16. https://doi.org/10.1634/theoncologist.9-6-606
3. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107:309–30. https://doi.org/10.1007/s10549-007-9556-1
4. Krishnamurthy S. Current applications and future prospects of fine-needle aspiration biopsy of locoregional lymph nodes in the management of breast cancer. Cancer. 2009;117:451–62. https://doi.org/10.1002/ency.20055
5. Blumgart EL, Uren RF, Nielsen PM, Nash MP, Reynolds HM. Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer. Breast Cancer Res Treat. 2011;130:699–705. https://doi.org/10.1007/s10549-011-1737-2
6. Estouargie SH, Nieweg OE, Olmos RA, Rutgers EJ, Kroon BB. Lymphatic drainage patterns from the breast. Ann Surg. 2004;239:232–7. https://doi.org/10.1097/01.SLA.0000109156.26378.90
7. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. https://doi.org/10.1016/annonc/mdz173
8. Pilewske M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3:549–55. https://doi.org/10.1001/jamaoncol.2016.4163
9. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8. https://doi.org/10.1200/JCO.2015.64.0094
10. Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012;36:2239–51. https://doi.org/10.1007/s00268-012-1625-2
11. Patten DK, Zacharioudakis KE, Chauhan H, Cleator SJ, Hadjiminas DJ. Sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with breast cancer: are the current false negative rates acceptable? Breast. 2015;24:318–20. https://doi.org/10.1016/j.breast.2015.02.026
12. Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American Joint Committee on Cancer’s Staging System for Breast Cancer, eighth edition: what the radiologist needs to know. Radiographics. 2018;38:1921–33. https://doi.org/10.1148/radiographics.2018180056
13. Liu XH, Zhang L, Chen B. A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer. Chronic Dis Transl Med. 2015;1:236–42. https://doi.org/10.1016/j.cdtrm.2016.01.002
14. Li L, Zhang H, Wang L, Xie C, Zhou Y, Zhong Y. A retrospective analysis on metastatic rate of the internal mammary lymph node and its clinical significance in adjuvant radiotherapy of breast cancer patients. BMC Cancer. 2020;20:153. https://doi.org/10.1186/s12885-020-06642-9
15. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. https://doi.org/10.1093/annonc/mdz173
16. Bruckmann NM, Sawicki LM, Kirchner J, Martin O, Umutlu L, Herrmann K, et al. Prospective evaluation of whole-body MRI and (18)F-FDG PET/MRI in N and M staging of primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04801-2
17. Morawitz J, Kirchner J, Martin O, Bruckmann NM, Dietzel F, Li Y, et al. Prospective correlation of prognostic immunohistochemical markers with SUV and ADC derived from dedicated hybrid breast 18F-FDG PET/MRI in women with newly diagnosed breast cancer. Clin Nucl Med. 2021;46:201–5. https://doi.org/10.1097/RLU.0000000000003488
18. Banjar FK, Wilson AM. Anatomy, head and neck, supraclavicular lymph node. StatPearls. Treasure Island (FL); 2020.

19. Pitcha JK. Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview. Chin Clin Oncol. 2019;8:S11. https://doi.org/10.21037/ccoj.c2019.01.09.

20. Urano M, Denewar FA, Murai T, Mizutani M, Kitase M, Ohashi K, et al. Internal mammary lymph node metastases in breast cancer: what should radiologists know? Jpn J Radiol. 2018;36:629–40. https://doi.org/10.10111/abj.13102.

21. Patel S, Delikat A, Liao J, Chethlen AL, Pre- and post-magnetic resonance imaging features of suspicious internal mammary lymph nodes in breast cancer patients receiving neo-adjuvant therapy: are any imaging features predictive of malignancy? Breast. 2018;24:997–1000. https://doi.org/10.1111/bdj.13102.

22. Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary lymph node. StatPearls. Treasure Island (FL); 2020.

23. Murray AD, Staff RT, Redpath TW, Gilbert FJ, Ah-See AK, Brookes JA, et al. Dynamic contrast enhanced MRI of the axilla in women with breast cancer: comparison with pathology of excised nodes. Br J Radiol. 2002;75:220–8. https://doi.org/10.1259/bjr.75.891.750220.

24. Baltzer PA, Dietzel M, Burmeister HP, Zoubi R, Gajda M, Camara O, et al. Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? Evaluation of an extended protocol in an initial prospective study. AJR Am J Roentgenol. 2011;196:W641–7. https://doi.org/10.2214/AJR.10.4889.

25. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy. Radiology. 2003;229:526–33. https://doi.org/10.1016/S0022-3418(03)00152-0.

26. Takahashi Y, Soh J, Shien K, Yamamoto H, Yamane M, Kitara K, et al. Fibrosis or necrosis in resected lymph node indicate metastasis before chemoradiotherapy in lung cancer patients. Anticancer Res. 2020;40:4419–23. https://doi.org/10.21873/anticancerres.14447.

27. Newman LA, Pernick NL, Adsay V, Carolin KA, Philip PA, Sipierski S, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol. 2003;10:734–9. https://doi.org/10.1245/sao.2003.03.081.

28. Alvarez S, Amorbe E, Alcorta P, Lopez F, Alonso I, Cortes J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol. 2006;186:1342–8. https://doi.org/10.2214/AJR.05.0936.

29. Ogasawara Y, Dohira H, Shiraawa M, Ishihara S. Multidetector-row computed tomography for the preoperative evaluation of axillary nodal status in patients with breast cancer. Surg Today. 2008;38:104–8. https://doi.org/10.1007/s00595-007-3589-2.

30. Kuijs VJ, Moosdorff M, Schipper JP, Beets-Tan RG, Heuts EM, Keymeulen KB, et al. The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review. Insights Imaging. 2015;6:203–15. https://doi.org/10.1007/s13244-015-0404-2.

31. Chayakulkheeree J, Pungrassami D, Prueskaede J. Performance of breast magnetic resonance imaging in axillary nodal staging in newly diagnosed breast cancer patients. Pol J Radiol. 2019;84:e413–8. https://doi.org/10.5114/pjr.2019.89690.

32. van Nijmatten TJA, Goorts B, Voo S, de Boer M, Kooreman LFS, Heuts EM, et al. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study. Eur J Nucl Med Mol Imaging. 2018;45:179–86. https://doi.org/10.1007/s00259-017-3823-0.

33. Taneja S, Jena A, Goel R, Sarin R, Kaul S. Simultaneous whole-body (18)F-FDG PET/MRI in primary staging of breast cancer: a pilot study. Eur J Radiol. 2014;83:2231–9. https://doi.org/10.1016/j.ejrad.2014.09.008.

34. Cooper KL, Meng Y, Harnan S, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2015;15:iii–iv:1–134. https://doi.org/10.3310/hta15040.

35. Ueda S, Tsuda H, Asakawa H, Omata M, Fukatsu K, Kondo N, et al. Utility of 18F-fluorodeoxyglucose emission/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;8:165. https://doi.org/10.1186/1471-2407-8-165.

36. Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg. 2009;33:943–9. https://doi.org/10.1007/s00268-009-9955-z.

37. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, Group PETS. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277–85. https://doi.org/10.1200/JCO.2004.04.148.

38. Yates L, Kirby A, Crichton S, Gillett C, Cane P, Fentiman I, et al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys. 2012;82:2093–103. https://doi.org/10.1016/j.ijrobp.2011.01.066.

39. Budach W, Bolke E, Kammers K, Gerber PA, Nestle-Kramling M, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials - an update. Radiat Oncol. 2015;10:258. https://doi.org/10.1186/s13014-015-0568-4.

40. Uren RF, Howman-Giles R, Renwick SB, Gillett D. Lymphatic mapping of the breast: locating the sentinel lymph nodes. World J Surg. 2001;25:789–93. https://doi.org/10.1007/s00268-001-0006-7.

41. Groheux D, Moretti JL, Baillelet G, Espie M, Giachetti S, Hindie E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71:695–704. https://doi.org/10.1016/j.ijrobp.2008.02.056.

42. Mack M, Chethlen A, Liao J. Incidental internal mammary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2015;15(iii–iv):1–134.

43. Sachdev S, Goodman CR, Neuschler E, Kalakota K, Cutright JD. (18)F-FDG PET/CT-positive internal mammary lymph nodes: pathologic correlation by ultrasound-guided fine-needle aspiration and assessment of associated risk factors. AJR Am J Roentgenol. 2013;200:1138–44. https://doi.org/10.2214/AJR.12.8754.

44. Sachdev S, Goodman CR, Neuschler E, Kalakota K, Cutright D, Donnelly ED, et al. Radiotherapy of MRI-detected involved internal mammary lymph nodes in breast cancer. Radiat Oncol. 2015;20:209–14. https://doi.org/10.2214/AJR.14.13586.

45. Wang CL, Eissa MJ, Rogers JV, Aravkin YI, Porter BA, Beatty JD. (18)F-FDG PET/CT-positive internal mammary lymph nodes: pathologic correlation by ultrasound-guided fine-needle aspiration and assessment of associated risk factors. AJR Am J Roentgenol. 2013;200:1138–44. https://doi.org/10.2214/AJR.12.8754.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Janna Morawitz1 · Nils-Martin Bruckmann1 · Frederic Dietzel1 · Tim Ullrich1 · Ann-Kathrin Bittner2 · Oliver Hoffmann2 · Eugen Ruckhäberle3 · Svjetlana Mohrmann3 · Lena Häberle4 · Marc Ingenwerth5 · Daniel Benjamin Abrar1 · Lino Morris Sawicki1 · Katharina Breuckmann6 · Wolfgang Peter Fendler7 · Ken Herrmann7 · Christian Buchbender1 · Gerald Antoch1 · Lale Umutlu6 · Julian Kirchner1

1 Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225 Dusseldorf, Germany
2 Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany
3 Department of Gynecology, Medical Faculty, University Dusseldorf, 40225 Dusseldorf, Germany
4 Institute of Pathology, Medical Faculty, Heinrich-Heine-University and University Hospital Dusseldorf, Duesseldorf, Germany
5 Institute of Pathology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany
6 Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany
7 Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany